Efficacy of the topical therapy with Tacrolimus in case of atopic dermatitis in adults
- 作者: BAKULEV AL1, KRAVCHENYA SS1
-
隶属关系:
- ГБОУ ВПО «Саратовский ГМУ им. В.И. Разумовского» Минздрава России
- 期: 卷 88, 编号 5 (2012)
- 页面: 106-111
- 栏目: Articles
- URL: https://ogarev-online.ru/0042-4609/article/view/117248
- DOI: https://doi.org/10.25208/vdv738
- ID: 117248
如何引用文章
全文:
详细
Objective: to assess the efficacy and safety of 0.1% Tacrolimus ointment in case of atopic dermatitis in adults during the period of exacerbation. Materials and methods. The authors conducted a study of 60 patients (37 male and 23 female patients) with atopic dermatitis aged 22—45 during the period of exacerbation. Topical therapy with Tacrolimus (0.1% ointment) was administered to 22 patients once a day for 14 days. A topical glucocorticosteroid belonging to the 3rd bioactivity class according to the European classification of topical glucocorticosteroids (Miller, Munro) (0.1% methylprednisolone aceponate ointment) was administered for the treatment of 38 patients suffering from atopic dermatitis. For the purposes of unbiased assessment of the efficacy and safety of the topical therapy with different drugs, the authors performed an ultrasonic skin examination using a digital ultrasonic high-resolution system, DUB (manufactured by TPM GmbH). Results: In the course of the therapy, the authors observed a reliable reduction in the prevalence and severity of dermatosis as well as normalization of a number of ultrasonic indices of epidermis and derma. Conclusion: The therapeutic efficacy of short-term administration of Tacrolimus is comparable by its anti-inflammatory action to such potent topical glucocorticosteroid as methylprednisolone aceponate. Unlike the topical glucocorticosteroid, administration of Tacrolimus for exacerbated atopic dermatitis does not accelerate any skin atrophy phenomena.
作者简介
A BAKULEV
ГБОУ ВПО «Саратовский ГМУ им. В.И. Разумовского» Минздрава России
Email: al_ba05@mail.ru
д.м.н., профессор, профессор кафедры кожных и венерических болезней
S KRAVCHENYA
ГБОУ ВПО «Саратовский ГМУ им. В.И. Разумовского» Минздрава Россиик.м.н., заведующий отделением
参考
- Katsambas A.D., Lotti T.M. European Handbook of Dermatological Treatments. Springer. 2003; 855.
- Wollenberg A., Bieber T. FK-506/Tacrolimus. In: Burg G., Dummer R.G., editors.Strategies for Immunointerventions in Dermatology. SpringerVerlag, Heidelberg, 1997: 53—57.
- Walker Metry D., Herbert A.A.Topical therapies and medications in the pediatric patient.Pediatr Dermatol 2000; 47: 867—876.
- McAlister R.O. Tacrolimus: a promising new therapy for eczema/atopic dermatitis.Advocate 1999; 11: 1—9.
- Клинические рекомендации по ведению больных атопическим дерматитом под ред. А.А. Кубановой. М.: ДЭКС-Пресс 2010; 40.
- FK506 Ointment Study Group. Phase II !comparative study on FK506 ointment: intergroup comparative study on FK506 ointment and betamethasone valerate ointment in the treatment of atopi cdermatitis (of the trunk and limbs). Nishi Nihon J Dermatol 1997; 59: 870—879.
- FK506 Ointment Study Group. Phase III comparative study on FK 506 ointment and aclometasone diproprionate ointment in the treatment of atopic dermatitis. Acta Dermatol 1997; 92: 277—288.
- Doss N., Reitamo S., Dubertret L. et al., Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol 2009.
- Doss N., Kamoun M.-R., Dubertret L. et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. BJD 2009; 161: 427—434.
- Korting H.C., Unholzer A., Schafer-Korting M. et al. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002; 15: 85—91.
- Kerscher M.J., Hart H., Korting H.C., Stalleicken D. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid, as compared to other topical glucocorticoids, old and new. Int J Clin Pharmacol Ther 1995; 33 (4): 187—189.
- Haapasaari K.M., Risteli J., Oikarinen A. Recovery of human skin collagen synthesis after short-term topical corticosteroid treatment and comparison between young and old subjects. Brit J Dermatol 1996; 135: 65—69.
补充文件
